All In Biotech

Drug Trial Radar · NCT05599789

Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)

A Phase 2 Study of Pembrolizumab in Combination With Plinabulin and Docetaxel in Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer and Progressive Disease (PD) After Immunotherapy (Anti-PD-1/PD-L1 Inhibitor) Alone or in Combination With Platinum-doublet Chemotherapy (KeyPemls-004)

Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

47

Planned (sponsor's estimate)

Start

Feb 1, 2023

Primary completion

May 21, 2025

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Peking Union Medical College HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
BeyondSpring Pharmaceuticals Inc.; Merck Sharp & Dohme LLC
First posted
Oct 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2 Study of Pembrolizumab in Combination with Plinabulin and Docetaxel in previously treated Patients with Metastatic Non-Small Cell Lung Cancer and progressive disease (PD) after immunotherapy (Anti-PD-1/PD-L1 inhibitor) alone or in combination with Platinum-doublet Chemotherapy.

Conditions

  • Non Small Cell Lung Cancer Metastatic

Interventions

  • Pembrolizumab in Combination with Plinabulin and DocetaxelDrug

    Pembrolizumab 200 mg Q3W IV infusion Day 1 of each 3-week cycle; Plinabulin 30 mg/m2 Q3W IV infusion Days 1 of each 3-week cycle; Docetaxel 75 mg/m² Q3W IV infusion Day 1 of each 3-week cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORR, objective response rateTime frame: through study completion, an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.